Proof-of-concept HIV immunotherapy study passes Phase 1 safety trial

[From Eureka Alert, Sept 21, 2018]

“Preliminary results from a phase I clinical trial have demonstrated the safety and tolerability of a cell therapy involving the ex vivo expansion of T cells and their subsequent infusion into HIV-infected individuals previously treated with antiretroviral therapy (ART). The study appears September 21st in the journal Molecular Therapy.”

For more, click here.

Leave a Comment

Scroll to Top